**California voters will decide Proposition 38 on November 3, 2026, which would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, split evenly between grants to public and nonprofit institutions and a single UC-affiliated research institute selected by the Department of Public Health, with half the funds directed to cancer, heart disease, and Alzheimer’s work.** The measure carries an estimated $500–600 million annual General Fund repayment cost for roughly 20–25 years, offset only partially by potential future royalties or licensing revenue. Opposition has centered on the added long-term debt burden, the earmark for one predetermined-style recipient, and questions about administrative controls and pricing mandates. These fiscal and structural concerns appear to underpin the current trader consensus favoring rejection, even as disease advocacy groups continue to promote the initiative as a state-level response to federal research funding pressures.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডCalifornia Immunology Research Bond Proposition
California Immunology Research Bond Proposition
44% সম্ভাবনা
নতুন
নতুন
Nov 3, 2026
44% সম্ভাবনা
নতুন
নতুন
Nov 3, 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).**California voters will decide Proposition 38 on November 3, 2026, which would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, split evenly between grants to public and nonprofit institutions and a single UC-affiliated research institute selected by the Department of Public Health, with half the funds directed to cancer, heart disease, and Alzheimer’s work.**
The measure carries an estimated $500–600 million annual General Fund repayment cost for roughly 20–25 years, offset only partially by potential future royalties or licensing revenue. Opposition has centered on the added long-term debt burden, the earmark for one predetermined-style recipient, and questions about administrative controls and pricing mandates. These fiscal and structural concerns appear to underpin the current trader consensus favoring rejection, even as disease advocacy groups continue to promote the initiative as a state-level response to federal research funding pressures.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
মার্কেট ওপেন হয়েছে: Jul 1, 2026, 6:33 PM ET
ভলিউম
$2,892শেষ তারিখ
Nov 3, 2026মার্কেট ওপেন হয়েছে
Jul 1, 2026, 6:33 PM ETরেজলভার
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).**California voters will decide Proposition 38 on November 3, 2026, which would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, split evenly between grants to public and nonprofit institutions and a single UC-affiliated research institute selected by the Department of Public Health, with half the funds directed to cancer, heart disease, and Alzheimer’s work.**
The measure carries an estimated $500–600 million annual General Fund repayment cost for roughly 20–25 years, offset only partially by potential future royalties or licensing revenue. Opposition has centered on the added long-term debt burden, the earmark for one predetermined-style recipient, and questions about administrative controls and pricing mandates. These fiscal and structural concerns appear to underpin the current trader consensus favoring rejection, even as disease advocacy groups continue to promote the initiative as a state-level response to federal research funding pressures.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ভলিউম
$2,892শেষ তারিখ
Nov 3, 2026মার্কেট ওপেন হয়েছে
Jul 1, 2026, 6:33 PM ETরেজলভার
0x65070BE91...**California voters will decide Proposition 38 on November 3, 2026, which would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, split evenly between grants to public and nonprofit institutions and a single UC-affiliated research institute selected by the Department of Public Health, with half the funds directed to cancer, heart disease, and Alzheimer’s work.** The measure carries an estimated $500–600 million annual General Fund repayment cost for roughly 20–25 years, offset only partially by potential future royalties or licensing revenue. Opposition has centered on the added long-term debt burden, the earmark for one predetermined-style recipient, and questions about administrative controls and pricing mandates. These fiscal and structural concerns appear to underpin the current trader consensus favoring rejection, even as disease advocacy groups continue to promote the initiative as a state-level response to federal research funding pressures.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা